Pharma's Reform Bounce: How Big A Boost Will $80 Bil. Buy
Executive Summary
The introduction of the Senate Finance Committee's health care proposal turns the focus from what the pharmaceutical industry will contribute to reform efforts toward what manufacturers stand to gain
You may also be interested in...
Betting and Winning: SCOTUS Decision Underscores High Stakes In Pharma’s Strategy
The Supreme Court decision was a decisive victory for the biopharma industry for a number of reasons. But the drama that unfolded in a razor-close decision will continue as new milestones—political and legislative—approach.
Health Reform Bill Downsizing Would Send Pharma Back To Bargaining Table
The biopharmaceutical industry will look to renegotiate its financial contribution to health reform if congressional Democratic leaders determine that a much more modest bill is the best way forward following the loss of their 60-seat super-majority in the Senate
Health Reform Bill Downsizing Would Send Pharma Back To Bargaining Table
The biopharmaceutical industry will look to renegotiate its financial contribution to health reform if congressional Democratic leaders determine that a much more modest bill is the best way forward following the loss of their 60-seat super-majority in the Senate